NCT07316062 A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
| NCT ID | NCT07316062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Non-Small-Cell Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2026-04-29 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2026-04-29 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Eligibility Criteria
Inclusion Criteria: * Stage I-III at initial NSCLC diagnosis * Aged ≥18 years at first diagnosis of NSCLC * Timeframe of NSCLC diagnosis: For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027 Exclusion Criteria: * NSCLC is not the primary cancer diagnosis * Patients with a recent history of other tumor or concurrent other tumor * Patients participating in interventional clinical trials at time of initial diagnosis * Patients with positive pregnancy status at the time of diagnosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07316062 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small-Cell Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07316062 currently recruiting?
Yes, NCT07316062 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07316062 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07316062 clinical trial?
NCT07316062 is sponsored by AstraZeneca. The trial plans to enroll 3,000 participants.